---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-095423"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:11:38.455107+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nektar Q3 net loss narrows to $37.1M; sells Huntsville business for $90M

## Summary
- Net loss $37.1M ($0.18/sh) vs $45.8M ($0.24) in Q3 2023; revenue flat at $24.1M.
- Cash & investments $249M as of Sep 30; expected to fund operations into Q4 2026.
- Definitive agreement to sell Huntsville PEGylation business to Ampersand for $90M ($70M cash + $20M equity).
- R&D expense rose to $35.0M from $24.1M, driven by rezpegaldesleukin and NKTR-0165 development.
- Topline data for rezpegaldesleukin Phase 2b in atopic dermatitis expected H1 2025; alopecia areata H2 2025.

## SEC filing metadata
- accession: 0001213900-24-095423
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390024095423/0001213900-24-095423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390024095423/ea0220296-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-095423
- JSON: https://secwatch.observer/filing/0001213900-24-095423.json
- Plain text: https://secwatch.observer/filing/0001213900-24-095423.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.